Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Latest shares articles
Why Michael Burry just sold all his stocks
Michael Burry just sold over $70 million in stock, liquidating his entire portfolio except for one stock, doubling down on a company that other investors are fleeing in droves.
15 hours ago
An unprecedented signal just triggered on the US Dollar
The US dollar just collapsed against the Taiwanese new dollar, with the pairing falling 8% in just a few days, crashing below this key support line and reaching its lowest level in over a year.
14:17, 17 July 2025
Trading Gold’s short-term bull channel
Denial of Fed Chair Powell’s removal has meant a pullback off the highs, but what will it take to get gold prices to break out of its short-term bull channel?
07:23, 17 July 2025
Nasdaq 100: Trading US CPI
Futures up on Nvidia’s China sales resumption of AI chips, but the next test is US pricing data.
06:29, 15 July 2025
Ratings and Reviews
Ratings and Reviews
